<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="6775">Mesalamine</z:chebi> has been used as the first-line therapy for the treatment of <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> (UC) because of its efficacy and fewer side effects </plain></SENT>
<SENT sid="1" pm="."><plain>However, earlier study showed that <z:chebi fb="0" ids="6775">mesalamine</z:chebi> occasionally causes <z:hpo ids='HP_0002014'>diarrhea</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We are presenting a patient with active UC in whom <z:hpo ids='HP_0002573'>bloody diarrhea</z:hpo> accompanied by <z:hpo ids='HP_0002027'>abdominal pain</z:hpo> and <z:hpo ids='HP_0001945'>fever</z:hpo> occurred and the symptoms were aggravated after administration of <z:chebi fb="0" ids="6775">mesalamine</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>In order to clarify the reason of symptoms aggravation, drug lymphocyte stimulation test and rechallenge trial with <z:chebi fb="0" ids="6775">mesalamine</z:chebi> were performed </plain></SENT>
<SENT sid="4" pm="."><plain>The results indicated the possibility that aggravation was related to allergic reaction and was dose-dependent </plain></SENT>
<SENT sid="5" pm="."><plain>Furthermore, we examined colonoscopic views but there was no remarkable change in before and after rechallenge trial </plain></SENT>
<SENT sid="6" pm="."><plain>Based on the above result, the patient was diagnosed with <z:chebi fb="0" ids="6775">mesalamine</z:chebi> intolerance </plain></SENT>
<SENT sid="7" pm="."><plain>In order to differentiate whether the exacerbation of <z:hpo ids='HP_0002573'>bloody diarrhea</z:hpo> is due to the side effects of the <z:chebi fb="0" ids="6775">mesalamine</z:chebi> or a true relapse of UC, taking careful history before and after increasing <z:chebi fb="0" ids="6775">mesalamine</z:chebi> dosage as well as being aware of side effects of <z:chebi fb="0" ids="6775">mesalamine</z:chebi> are required </plain></SENT>
<SENT sid="8" pm="."><plain>Clinicians should be aware of <z:hpo ids='HP_0002014'>diarrhea</z:hpo> as a side effect of <z:chebi fb="0" ids="6775">mesalamine</z:chebi> particularly after <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:chebi fb="0" ids="6775">mesalamine</z:chebi> formulation, change in <z:chebi fb="0" ids="6775">mesalamine</z:chebi> formulation, or change in <z:chebi fb="0" ids="6775">mesalamine</z:chebi> dose </plain></SENT>
</text></document>